recombinant b. burgdorferi surface protein (outer-surface protein a; ospa)
Trade name: LYMErix
Vaccinewithdrawn
Approved
Dec 21, 1998
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1990s
- Dec 21, 1998
Earliest FDA Approval
Indications
Approved for
Mechanism of action
- Borrelia burgdorferiImmunity, active
Borrelia burgdorferi immunity, active
Approval history
- withdrawnDec 21, 1998
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- borrelia burgdorferi outer surface protein a
- lymerix
- lymerix
- ospa protein
- ospa protein, borrelia burgdorferi
- ospa vaccine
- outer surface protein a
- recombinant b. burgdorferi surface protein (outer-surface protein a; ospa)